These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22068660)

  • 1. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.
    Singh R; Zhang Y; Pastan I; Kreitman RJ
    Clin Cancer Res; 2012 Jan; 18(1):152-60. PubMed ID: 22068660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.
    Kreitman RJ; Stetler-Stevenson M; Jaffe ES; Conlon KC; Steinberg SM; Wilson W; Waldmann TA; Pastan I
    Clin Cancer Res; 2016 Jan; 22(2):310-8. PubMed ID: 26350263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
    Powell DJ; Felipe-Silva A; Merino MJ; Ahmadzadeh M; Allen T; Levy C; White DE; Mavroukakis S; Kreitman RJ; Rosenberg SA; Pastan I
    J Immunol; 2007 Oct; 179(7):4919-28. PubMed ID: 17878392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
    Decker T; Hipp S; Kreitman RJ; Pastan I; Peschel C; Licht T
    Blood; 2002 Feb; 99(4):1320-6. PubMed ID: 11830482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.
    Mazor R; Kaplan G; Park D; Jang Y; Lee F; Kreitman R; Pastan I
    Cell Immunol; 2017 Mar; 313():59-66. PubMed ID: 28087047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
    Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
    J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
    Hassan R; Broaddus VC; Wilson S; Liewehr DJ; Zhang J
    Clin Cancer Res; 2007 Dec; 13(23):7166-71. PubMed ID: 18056197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
    Robbins DH; Margulies I; Stetler-Stevenson M; Kreitman RJ
    Clin Cancer Res; 2000 Feb; 6(2):693-700. PubMed ID: 10690555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
    Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
    J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
    Liu D; Kojima T; Ouchi M; Kuroda S; Watanabe Y; Hashimoto Y; Onimatsu H; Urata Y; Fujiwara T
    Mol Cancer Ther; 2009 Apr; 8(4):980-7. PubMed ID: 19372571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
    Gold DV; Modrak DE; Schutsky K; Cardillo TM
    Int J Cancer; 2004 Apr; 109(4):618-26. PubMed ID: 14991585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
    Hanada M; Noguchi T; Yamaoka T
    Cancer Sci; 2007 Mar; 98(3):447-54. PubMed ID: 17214744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
    Gold DV; Schutsky K; Modrak D; Cardillo TM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3929S-37S. PubMed ID: 14506191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the
    Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
    Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.
    Cardillo TM; Blumenthal R; Ying Z; Gold DV
    Int J Cancer; 2002 Jan; 97(3):386-92. PubMed ID: 11774294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
    Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
    Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice.
    Beck AW; Luster TA; Miller AF; Holloway SE; Conner CR; Barnett CC; Thorpe PE; Fleming JB; Brekken RA
    Int J Cancer; 2006 May; 118(10):2639-43. PubMed ID: 16353142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
    Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
    Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.
    Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
    Anticancer Res; 2001; 21(5):3175-84. PubMed ID: 11848470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.